Bywall, Karin Schölin
Drevin, Jennifer
Groothuis-Oudshoorn, Catharina
Veldwijk, Jorien
Nyholm, Dag
Widner, Hakan
van Vliet, Trinette
Jiltsova, Elena
Hansson, Mats
Johansson, Jennifer Viberg
Funding for this research was provided by:
Uppsala University
Article History
Received: 17 March 2023
Accepted: 3 October 2023
First Online: 12 October 2023
Declarations
:
: Karin Schölin Bywall, Jennifer Drevin, Catharina Groothuis-Oudshoorn, Jorien Veldwijk, Trinette van Vliet, Elena Jiltsova, Mats Hansson, and Jennifer Viberg Johansson declare no conflict of interests. Dag Nyholm has received compensation for consultancies and/or lecturing from AbbVie, Britannia, NeuroDerm, NordicInfu Care, Sensidose and Stada. Hakan Widner has received compensation for education activities from pharmaceutical companies (Bristol Meyer Squibb, Abbott, Abbvie) and performed clinical studies with Herantis Pharma Y/O, Renishaw Ltd., and served as advisor to Novo Nordisk A/S on the use of pluripotent stem cells for clinical use in humans.
: This study was approved by the Swedish Ethical Review Authority (Etikprövningsmyndigheten, dnr 2019–06539). All participants provided informed consent to participate in the study. Data are presented in such a way that no individual can be identified. All research was carried out in accordance with relevant national and international guidelines and regulations.
: Not applicable.